Pharmafile Logo
Pharmafocus logo
Advanced Search

Haematology

Showing 15 posts of 38 posts found.

CytoSorbents announces EU launch and availability of PuriFi blood pump

June 14, 2024
Medical Communications CytoSorbents, EU, Haematology, PuriFi, blood pump

CytoSorbents Corporation has announced the launch and immediate availability of its PuriFi haemoperfusion machine in the EU following its approval …

News
yunus-tug-lnfgdbcajxu-unsplash

FDA approves Geron’s Rytelo for treatment of MDS with transfusion-dependent anaemia

June 7, 2024
Medical Communications FDA, Geron, Haematology, anaemia, mds

Geron Corporation has announced that the US Food and Drug Administration (FDA) has approved Rytelo (imetelstat) for the treatment of …

News
anirudh-djo3injpaoe-unsplash_3

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

April 29, 2024
Medical Communications FDA, Haematology, Pfizer, haemophilia

Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of …

News

Ironic Biotech announces $1m funding to develop iron deficiency and anaemia treatment

April 4, 2024
Sales and Marketing Haematology, Ironic Biotech, anaemia, funding, iron deficiency

Swedish biotech startup Ironic Biotech has announced that it has successfully closed a pre-seed funding round of $1m, led by …

News

AstraZeneca’s Voydeya recommended for approval in EU by CHMP

February 29, 2024
Medical Communications AstraZeneca, CHMP, EMA, Haematology, Voydeya

AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) by the Committee …

News

EC approves Vertex’s Casgevy for sickle cell disease treatment

February 13, 2024
Medical Communications Casgevy, European Commission, Haematology, Vertex pharmaceuticals, sickle cell disease

Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a CRISPR/Cas9 …

News
anirudh-djo3injpaoe-unsplash_3

AstraZeneca’s Voydeya approved in Japan for PNH treatment

January 19, 2024
Medical Communications AstraZeneca, Haematology, PNH, Voydeya

AstraZeneca has announced that Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), in …

News

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023
Medical Communications FDA, Fabhalta, Haematology, Novartis, PNH

Novartis has announced that the US Food and Drug Administration has approved Fabhalta (iptacopan) as the first oral monotherapy for …

News

MorphoSys shares phase 3 trial results for pelabresib in myelofibrosis treatment

November 23, 2023
Research and Development Haematology, clinical trial, morphosys, myelofibrosis, pelabresib

MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an investigational BET inhibitor, in combination …

News
testalize-me-0je8ynv4mis-unsplash

GSK gains positive CHMP opinion for momelotinib for myelofibrosis treatment

November 13, 2023
Medical Communications CHMP, GSK, Haematology, anaemia, momelotinib, myelofibrosis

GSK has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has …

News

Regeneron plans to share advancements from blood cancer pipeline

November 6, 2023
Medical Communications ASH annual meeting, Haematology, Regeneron, blood cancer, haematology

Regeneron Pharmaceuticals have announced that it plans to share new and updated data from its haematology pipeline at the American …

News

FDA grants ODD to Nexcella’s NXC-201 as treatment for amyloid light chain amyloidosis

September 22, 2023
Medical Communications FDA, Haematology, Nexcella, amyloidosis

Nexcella has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NXC-201 for …

News

GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia

September 18, 2023
Medical Communications FDA, GSK, Haematology, Ojjaara, anaemia, myelofibrosis

GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate …

News
blood-1813410_960_720

FDA approves BMS’s Reblozyl for treatment of anaemia in adults with lower-risk MDS

August 30, 2023
Research and Development FDA, Haematology, Reblozyl, anaemia, bristol myers squibb, myelodysplastic syndromes

Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the …

News
blood-1813410_960_720

Hutchmed announces phase 3 trial met primary endpoint for primary immune thrombocytopenia treatment

August 21, 2023
Research and Development HUTCHMED, Haematology, clinical trial, sovleplenib, thrombocytopenia

Hutchmed has announced that its phase 3 trial ESLIM-01 trial assessing the use of sovleplenib has met its primary endpoint …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025